

**Prevalence of Benign Breast Lesions, Epithelial Proliferations with or Without Atypia in Calabar-A Retrospective Review.**

**ABSTRACT.**

**AIMS:** The aim of this study is to find out the prevalence of benign breast lesions and proliferative lesions which are associated with increase risk of breast cancer. This is aimed at influencing the hospital policy on mammographic screening.

**Study Design:** Descriptive retrospective study involving a trend analysis of benign breast lesion, proliferative analysed in the surgical pathology unit of the University of Calabar Teaching Hospital between 1st of January 2012 to October 31st 2014.

**Place and Duration of Study.** Pathology department of the University of Calabar Teaching hospital. The study was carried out between March and April 2019.

**Methodology:** Descriptive retrospective study of trend analysis of benign and proliferative breast lesions over the period with literature review.

**Results:** Two hundred and seventeen 217 patients consisting of seven males and two hundred and ten females with a female: male ratio of 1:0.04. Mean age was  $26.4 \pm 10.0$  years, ranging from 10 to 70 years, with 21-30 (94, 43.5%), as the predominant age and less than 21 years (70, 32.4%) as the second common age group. Seventy four percent of (74%) of the breast lesions were benign non proliferative lesions while 26% were proliferative breast lesions. Of the proliferative lesions, five or 8.9% of the proliferative or 2.33% of the lesions were atypical ductal hyperplasia's which have a high risk of progression to cancer.

**Conclusion:** Proliferative breast lesions and the premalignant lesions of the breast are not commonly reported in Calabar. An upscale of population screening and mammographic services may improve their yield which will help prevent some invasive breast cancers.

**Keywords:** *Proliferative, Benign, Breast, Calabar.*

**1 INTRODUCTION:**

The discovery of a breast lump in Calabar-Nigeria as it is everywhere evokes such deep anxiety in the patients and relations, young and old alike(1). Myths about breast cancer still abound among Nigerians, uneducated and educated, because according to Anyanwu et al missed opportunities for breast cancer education fuel them(2). The generally young populations in sub-Saharan Africa are reflected in the low mean ages of breast cancer patients for instance, 44 years was reported by Anyanwu et al South east Nigeria, 49 years by Ikeri et al in Lagos Nigeria(3) and 46 years by Anakwenze et al in Botswana (4). There is a high rate of surgical treatment for breast lesions. The low per capita presence of ancillary radiological diagnostic tools and pathology service means that many of these lumps are not properly investigated before surgery. So, lesions that should ordinarily be managed conservatively end up being removed surgically.

41 Previous studies of benign breast lesions in Nigeria reported a preponderance of fibroadenoma,  
42 followed by Fibrocystic disease and inflammations such as acute and chronic mastitis in females and  
43 in males gynaecomastia(5-14).This compares favourably with other sub-Saharan African studies(15),  
44 and reports from other tropical settings(16).In the western world fibroadenoma or fibrocystic disease  
45 followed by radial scar/complex sclerosing lesion as well as atypical ductal hyperplasia and usual  
46 ductal hyperplasia were the common lesions (17).The risk stratification of benign lesions regarding  
47 association with breast cancer ranges from low, in non-proliferative types to intermediate in the case  
48 of benign epithelial proliferations(18-23).In the case of fibroadenomas Ben Hassouna et al reported  
49 four cases of breast cancer arising from fibroadenoma(24).Although in two of these cases, the  
50 fibroadenomas were complex, with cystic areas, adenosis, apocrine metaplasia,whereas the other  
51 case had fibrocystic dysplasia and lobular neoplasia in adjacent parenchyma(24) Among the benign  
52 epithelial proliferations in which fibrocystic disease typifies, Cheng et al reported that a single breast  
53 lump may present with heterogenous histology, sometimes, the components may bear different risk  
54 profiles(25).This kind of expression they term Heterogenous benign breast disease HBBD(25).

55 The current concept presupposes that ductal epithelial proliferations are a direct precursor to breast  
56 cancer(26),and the spectrum ranges from usual ductal hyperplasia, through atypical ductal  
57 hyperplasia to carcinoma in situ and invasive carcinoma(26).While at the usual ductal hyperplasia  
58 stage the cell is still benign, it has however taken the committed step towards malignancy(27, 28).It  
59 will then progress through atypical ductal hyperplasia stage to cancer(27, 28).Although the Nurses  
60 commissioned study concluded that the extent of atypicality did not directly correlate with the  
61 transformation to cancer(29),as one would expect. The risk of association of atypical lesions of the  
62 breast were further demonstrated in a study by Anastasiadis et al in Greece who found that in frozen  
63 section examination of breast specimens , fibro adenosis tended to occur with benign breast lesions  
64 while atypical ductal hyperplasia tended to occur with breast cancer(30).

## 65 2 MATERIALS AND METHODS.

66 A trend analysis of benign breast lesions diagnosed at the department of Pathology University of  
67 Calabar Teaching Hospital between 1st of January 2012 to October 31st 2014 was carried out.Data  
68 extraction form comprised of Demographic, clinical and pathologic reports of these patients.Extracts  
69 comprised of, age,sex, symptoms type and duration, laterality of the lesions and diagnostic procedure  
70 as well as histological diagnosis. Only formalin fixed paraffin embedded breast tissue obtained by  
71 incision biopsy, excision biopsy and core needle biopsy were included in the study. Special stains and  
72 hormone receptor assays were not included in the study. Two hundred and seventeen (217) benign  
73 breast lesions were diagnosed during this period. Two were subsequently treated as missing data  
74 because they had no specific diagnosis other than they are being called benign lesions. The data  
75 was fed into IBM spss statistical data package version 21.0.The data was entered according to the  
76 classes of benign breast diseases proposed by Page et al 1985 which recognised proliferative and  
77 non-proliferative benign lesions as the two broad groups(31)

## 78 3 RESULTS

79 Data was obtained from 217 subjects consisting of seven males and two hundred and ten females  
80 with a female: male ratio of 1:0.04. Mean age was  $26.4 \pm 10.0$  years, ranging from 10 to 70 years,  
81 with 21-30 (94, 43.5%),as the predominant age and less than 21 years (70, 32.4%) as the second  
82 common age group (table 1).

**Table 1: Sociodemographic characteristics of subjects (N=217)**

<b>Variable</b>	<b>Frequency</b>	<b>Percentage</b>
<b>Sex</b>		
Male	7	3.2
Female	210	96.8
Total	217	100
<b>Age groups</b>		
<21	70	32.4
21-30	94	43.5
31-40	29	13.4

41-50	19	8.8
51-60	1	0.5
61-70	3	1.4
Total	216	100

83

84 Table 2 shows that most of these breast diseases (166, 89.3%) occurred on the right (87, 46.8%) or  
85 left (79, 42.5%) sides, with approximately one-tenth (20, 10.8%) occurring on both sides (table 2).  
86 Painless lump (167, 85.6%) was the commonest presenting complain. Two subjects (1.0%) each, had  
87 bloody and non-bloody nipple discharge. Mean duration of presenting complain was  $21.2 \pm 30.5$   
88 months, ranging from less than one to 240 months.

**Table 2: Morphologic and clinical presentation of benign breast disease and, proliferative disease, with or without atypia (N=217)**

Variable	Frequency	Percentage
<b>Side of breast</b>		
Right	87	46.8
Left	79	42.5
Both	20	10.8
Total	186	100
<b>Presenting complain</b>		
Painless lump	167	85.6
Painful lump	23	11.8
Bloody nipple discharge	2	1
Non-bloody nipple discharge	2	1
Multiple symptoms	1	0.5
Total	195	100

89

90 Histologic findings consisted breast disease without proliferative activity (159,74.0%)( table 3),the  
91 proliferative lesions comprised of of benign epithelial proliferations, proliferative without atypia and  
92 proliferative with atypia (56, 26.0%) (table 3). Of the fibrocystic disease, unqualified fibrocystic change  
93 (38, 86.4%) was the commonest of the benign epithelial proliferative forms. Intraductal papilloma (5,  
94 71.4%) was the commonest proliferative lesion without atypia, while atypical ductal hyperplasia (5,  
95 100%) was the only form of proliferative lesion with atypia. Fibroadenoma (121, 76.1%) was the  
96 commonest form of benign breast disease without proliferation. All the cases of gynecomastia (7,  
97 4.4%) were found in males.

98

**Table 3: Histologic types of benign and proliferative breast diseases seen at UCTH (N=215)**

Histology	Frequency	Percentage
<b>Benign breast diseases (n=159)</b>		
Fibroadenoma	121	76.1
Gynecomastia	7	4.4
Periductal mastitis	4	2.5
Lipoma	4	2.5
Fat necrosis	4	2.5
Tubular adenoma	3	1.9
Juvenile papillomatosis	3	1.9
Granulomatous mastitis	3	1.9
Granulation tissue	2	1.3
Benign phylloides	2	1.3
Mastitis	2	1.3
Lymphocytic mastitis	1	0.6

Granular cell myoblastoma	1	0.6
Lactating adenoma	1	0.6
Myofibroblastoma	1	0.6
<b>Total</b>	<b>159</b>	<b>100</b>
<b>Benign epithelial proliferative diseases (n=44)</b>		
Fibrocystic change (unqualified)	38	86.4
Duct ectasia	3	6.8
Blunt duct adenosis	2	4.5
Mild epithelial hyperplasia	1	2.3
Total	44	100
<b>Proliferative Without Atypia (N=7)</b>		
Intraductal papilloma / papillomatosis	5	71.4
Sclerosing adenosis	1	14.3
Moderate ductal hyperplasia	1	14.3
Total	7	100
<b>Proliferative with atypia (n=5)</b>		
Atypical ductal hyperplasia	5	100
Total	5	100

100 The mean age of patients with proliferative disease was 33.3 ±9 and this was statistically significant  
101 when compared to the mean age of the non-proliferative group, 24.0 ±9.1, table 4.

**Table 4: Relationship between mean age and histomorphologic characteristics  
(N=215)**

Variable	mean age ± SD	t-test	p-value
Proliferative disease	33.3 ± 9.2	6.52	0.00
Benign non proliferative disease	24.0 ± 9.1		

102

#### 103 4 DISCUSSION:

104 Benign non proliferative lesions of the breast were the commonest lesions 159(74.0%) in females in  
105 our study. Of these lesions Fibroadenoma (76%),is the commonest benign non-proliferative lesion,  
106 mirroring other Nigerian studies(14, 32-36). Other benign lesions in the female breast in our study  
107 were Periductal mastitis,lipomas,fat necrosis, tubular adenoma, Juvenile papillomatosis,  
108 granulomatous mastitis, granulation tissue, benign phyllodes, acute mastitis, lymphocytic  
109 mastitis,granular cell myoblastoma,lactating adenoma and myofibroblastoma all of which account for  
110 less than 30 percent.By comparison fibrocystic disease,followed by fibroadenoma and complex  
111 sclerosing lesions are commoner in reports from the developed world(17).Although the rate of non  
112 proliferative lesions(37)(67%),in a fifteen year Mayo clinic cohort study in the United states, compares  
113 with our findings. Baum,M reviewed the impact of these lesions on the patients and concluded that  
114 the cost lies on the anxiety that they may be cancerous and the cosmetic deformity from multiple  
115 biopsies that often accompany them(1).Surgical treatment of these benign lesions tends to be  
116 common in our setting and diagnosis commonly relies on clinical assessment alone.Egwuonwu et al  
117 in south east Nigeria studied the reliability of clinical diagnosis of fibroadenoma in women 25 years  
118 and below, and reported a high sensitivity of 93.3%but a low specificity of 58.8%(38).In this age group  
119 non operative management of fibroadenoma may be an option if the other factors are favourable. And  
120 in adolescents well investigated, conservative management of small sized fibroadenoma is  
121 recommended (39, 40).Equally imaging in this age group differs from adults because of the rarity of  
122 cancer in this age(39).A few fibroadenomas may show proliferative activities, however both non  
123 proliferative and proliferative types of fibroadenomas are associated with low risk of breast cancer(41,  
124 42).

125 The proliferative lesions comprising of benign epithelial proliferations (BEP), proliferative breast  
126 diseases without atypia and proliferative breast diseases with atypia accounted for 26% of the  
127 cases.BEP comprised of Fibrocystic disease(unqualified)(17.7%),others are duct ectasia, blunt duct  
128 adenosis and mild epithelial hyperplasia. The frequency of fibrocystic disease in this study compares  
129 with some Nigerian series,for example 16.5% was reported by Adeniji et al in South-West  
130 Nigeria(5),Anyikam22.9% in South -East Nigeria(8).Our results were lower than some Nigerian  
131 series, for instance Adesunkanmi reported 42.2% in South-West Nigeria(6).This is equally lower than  
132 reports in western and Afro Caribbean literature(43),where it is often reported as the commonest  
133 BBD(44, 45).Lesions in this group do not just attract a passing interest, because there are  
134 documented low risk of association with breast cancers(37, 46).There is a tendency however to lump  
135 these lesions with all proliferative lesions in one basket with a heard risk of 1.5 to 3.0% when the  
136 generalizing term of fibrocystic disease is used (44).

137 In our review, proliferative lesions without atypia were 7(3.3%), with individual lesions being:ductal  
138 papilloma/ papillomatosis, sclerosing adenosis and moderate ductal hyperplasia.Radial scar or  
139 complex sclerosing lesion was a notably absent in our series.These lesions were comparatively fewer  
140 than 30% reported in the 15 years mayo clinic cohort study(37).One hopes that benign epithelial  
141 proliferations(fibrocystic disease),were not included in the non-proliferative lesions reported in the  
142 Mayo clinic study.These lesions are reported to pose level two risk (1.5% to 1.7%) of breast  
143 cancer(41, 47, 48),which is inferior to the level three risk pose by atypical proliferative lesions. The  
144 only proliferative lesion with atypia in our series is Atypical ductal hyperplasia which were  
145 5(2.3%).this number is slightly less than 4% reported in the Mayo clinic cohort study.(37).In terms of  
146 breast cancer risk these lesions are rated level 3 in the risk scale with cumulative risk of about 4-  
147 5%(48).It is now thought that many breast cancers arise through a multistep process which takes

148 them through ductal epithelial hyperplasia through atypical ductal hyperplasia, then carcinoma in situ  
149 before becoming invasive cancer(28).It is our belief in conclusion that as more and more screening  
150 mammography and other radiological tools are employed, the harvest of the high risk proliferative  
151 lesions will increase thereby preventing many invasive cancers.

152

### 153 **CONCLUSION:**

154 Benign breast lesions are diagnosed frequently as they should be in Calabar.But the high risk atypical  
155 lesions and the premalignant lesions are not frequently diagnosed.This is not unconnected to the lack  
156 of mammographic screening of the population.If this is routinely done it might help in reducing the  
157 incidence of invasive breast cancer.

158 **CONSENT:** Not applicable.

### 159 **ETHICAL APPROVAL:**

160 Ethical approval was granted by the institutional ethical review board.

161

162

### 163 **COMPETING INTEREST:**

164 The authors declare no competing interest

165

### 166 **REFERENCES:**

- 167 1. Baum M. Benign breast disease: the cost of the service and the cost to the patient. *World J*  
168 *Surg.* 1989;13(6):669-73.
- 169 2. Anyanwu LJ, Anyanwu OM, Yakubu AA. Missed opportunities for breast awareness  
170 information among women attending the maternal and child health services of an urban  
171 tertiary hospital in Northern Nigeria. *J Cancer Res Ther.* 2016;12(2):765-9.
- 172 3. Ikeri NZ, Oguntunde OA, Igbokwe U, Abdulkareem FB, Banjo AA. Breast Cancer in a Lagos  
173 Facility: Implications for the Institution of a Cancer Screening Programme. *Pathobiology.*  
174 2018;85(4):254-60.
- 175 4. Anakwenze C, Bhatia R, Rate W, Bakwenabatsile L, Ngoni K, Rayne S, et al. Factors Related to  
176 Advanced Stage of Cancer Presentation in Botswana. *J Glob Oncol.* 2018;4:1-9.
- 177 5. Adeniji KA, Adelusola KA, Odesanmi WO. Benign disease of the breast in Ile-Ife: a 10 year  
178 experience and literature review. *Cent Afr J Med.* 1997;43(5):140-3.
- 179 6. Adesunkanmi AR, Agbakwuru EA. Benign breast disease at Wesley Guild Hospital, Ilesha,  
180 Nigeria. *West Afr J Med.* 2001;20(2):146-51.
- 181 7. Ajao OG. Benign breast lesions. *J Natl Med Assoc.* 1979;71(9):867-8.
- 182 8. Anyikam A, Nzegwu MA, Ozumba BC, Okoye I, Olusina DB. Benign breast lesions in Eastern  
183 Nigeria. *Saudi Med J.* 2008;29(2):241-4.
- 184 9. Ibitoye BO, Adetiloye VA, Aremu AA. The appearances of benign breast diseases on  
185 ultrasound. *Niger J Med.* 2006;15(4):421-6.
- 186 10. Ihekweba FN. Benign breast disease in Nigerian women: a study of 657 patients. *J R Coll Surg*  
187 *Edinb.* 1994;39(5):280-3.
- 188 11. Kathy KC, Datubo-Brown DD, Gogo-Abite M, Iweha UU. Benign breast lesions in Nigerian  
189 women in Rivers State. *East Afr Med J.* 1990;67(3):201-4.
- 190 12. Olu-Eddo AN, Ugiagbe EE. Benign breast lesions in an African population: A 25-year  
191 histopathological review of 1864 cases. *Niger Med J.* 2011;52(4):211-6.
- 192 13. Osime OC, Ohanaka EC. Analysis of five-year breast biopsies carried out in the University of  
193 Benin Teaching Hospital Benin City. *Niger Postgrad Med J.* 2008;15(3):160-3.

- 194 14. Otu AA. Benign breast tumours in an African population. *J R Coll Surg Edinb.* 1990;35(6):373-  
195 5.
- 196 15. Okoth C, Galukande M, Jombwe J, Wamala D. Benign proliferative breast diseases among  
197 female patients at a sub-Saharan Africa tertiary hospital: a cross sectional study. *BMC Surg.*  
198 2013;13:9.
- 199 16. Chaudhuri M, Sen S, Sengupta J. Breast lumps: a study of 10 years. *J Indian Med Assoc.*  
200 1995;93(12):455-7.
- 201 17. Burnett SJ, Ng YY, Perry NM, Gilmore OJ, Allum WH, Carpenter R, et al. Benign biopsies in the  
202 prevalent round of breast screening: a review of 137 cases. *Clin Radiol.* 1995;50(4):254-8.
- 203 18. Amin TT, Al-Mulhim AR, Chopra R. Histopathological patterns of female breast lesions at  
204 secondary level care in Saudi Arabia. *Asian Pac J Cancer Prev.* 2009;10(6):1121-6.
- 205 19. Cote ML, Ruterbusch JJ, Alosch B, Bandyopadhyay S, Kim E, Albashiti B, et al. Benign breast  
206 disease and the risk of subsequent breast cancer in African American women. *Cancer Prev*  
207 *Res (Phila).* 2012;5(12):1375-80.
- 208 20. Dorjgochoo T, Deming SL, Gao YT, Lu W, Zheng Y, Ruan Z, et al. History of benign breast  
209 disease and risk of breast cancer among women in China: a case-control study. *Cancer*  
210 *Causes Control.* 2008;19(8):819-28.
- 211 21. Dupont WD, Parl FF, Hartmann WH, Brinton LA, Winfield AC, Worrell JA, et al. Breast cancer  
212 risk associated with proliferative breast disease and atypical hyperplasia. *Cancer.*  
213 1993;71(4):1258-65.
- 214 22. Dyrstad SW, Yan Y, Fowler AM, Colditz GA. Breast cancer risk associated with benign breast  
215 disease: systematic review and meta-analysis. *Breast Cancer Res Treat.* 2015;149(3):569-75.
- 216 23. Ferrara A. Benign breast disease. *Radiol Technol.* 2011;82(5):447M-62M.
- 217 24. Ben Hassouna J, Damak T, Ben Slama A, Chargui R, Ben Dhiab T, Khomsi F, et al. Breast  
218 carcinoma arising within fibroadenomas. Report of four observations. *Tunis Med.*  
219 2007;85(10):891-5.
- 220 25. Cheng J, Qiu S, Raju U, Wolman SR, Worsham MJ. Benign breast disease heterogeneity:  
221 association with histopathology, age, and ethnicity. *Breast Cancer Res Treat.*  
222 2008;111(2):289-96.
- 223 26. Boecker W, Buerger H, Schmitz K, Ellis IA, van Diest PJ, Sinn HP, et al. Ductal epithelial  
224 proliferations of the breast: a biological continuum? Comparative genomic hybridization and  
225 high-molecular-weight cytokeratin expression patterns. *J Pathol.* 2001;195(4):415-21.
- 226 27. Boecker W, Moll R, Dervan P, Buerger H, Poremba C, Diallo RI, et al. Usual ductal hyperplasia  
227 of the breast is a committed stem (progenitor) cell lesion distinct from atypical ductal  
228 hyperplasia and ductal carcinoma in situ. *J Pathol.* 2002;198(4):458-67.
- 229 28. Chinoy RF. Proliferative lesions of the breast: carcinoma in situ. *Indian J Pathol Microbiol.*  
230 2003;46(2):153-64.
- 231 29. Collins LC, Aroner SA, Connolly JL, Colditz GA, Schnitt SJ, Tamimi RM. Breast cancer risk by  
232 extent and type of atypical hyperplasia: An update from the Nurses' Health Studies. *Cancer.*  
233 2016;122(4):515-20.
- 234 30. Anastasiadis P, Romanidis K, Polychronidis A, Koutlaki N, Tamiolakis D, Simopoulos K.  
235 Proliferative breast disease: epidemiologic aspects, and cytologic diagnosis. *Eur J Gynaecol*  
236 *Oncol.* 2003;24(6):547-51.
- 237 31. Page D, William Dupoint, Lowell W. Rogers, Margaret S. Rados. <Page\_et\_al-1985-Cancer.pdf>.  
238 *Cancer.* 55:2698-708.
- 239 32. Mayun AA, Pindiga UH, Babayo UD. Pattern of histopathological diagnosis of breast lesions  
240 in Gombe, Nigeria. *Niger J Med.* 2008;17(2):159-62.
- 241 33. Oluwole SF, Freeman HP. Analysis of benign breast lesions in blacks. *Am J Surg.*  
242 1979;137(6):786-9.
- 243 34. Onukak EE, Cederquist RA. Benign breast disorders in nonwestern populations: Part III--  
244 Benign breast disorders in northern Nigeria. *World J Surg.* 1989;13(6):750-2.

- 245 35. Uwaezuoke SC, Udoye EP. Benign breast lesions in Bayelsa State, Niger Delta Nigeria: a 5  
246 year multicentre histopathological audit. *Pan Afr Med J.* 2014;19:394.
- 247 36. Ozumba BC, Nzegwu MA, Anyikam A, Okoye I, Okafor OC. Breast disease in children and  
248 adolescents in eastern Nigeria--a five-year study. *J Pediatr Adolesc Gynecol.* 2009;22(3):169-  
249 72.
- 250 37. Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K, et al. Benign breast  
251 disease and the risk of breast cancer. *N Engl J Med.* 2005;353(3):229-37.
- 252 38. Egwuonwu OA, Anyanwu S, Chianakwana GU, Ihekwoaba EC. Fibroadenoma: Accuracy of  
253 clinical diagnosis in females aged 25 years or less. *Niger J Clin Pract.* 2016;19(3):336-8.
- 254 39. Elsheikh A, Keramopoulos A, Lazaris D, Ambela C, Louvrou N, Michalas S. Breast tumors  
255 during adolescence. *Eur J Gynaecol Oncol.* 2000;21(4):408-10.
- 256 40. Duflos C, Plu-Bureau G, Thibaud E, Kuttenn F. Breast diseases in adolescents. *Endocr Dev.*  
257 2012;22:208-21.
- 258 41. Worsham MJ, Raju U, Lu M, Kapke A, Botttrel A, Cheng J, et al. Risk factors for breast cancer  
259 from benign breast disease in a diverse population. *Breast Cancer Res Treat.* 2009;118(1):1-  
260 7.
- 261 42. Moskowitz M, Gartside P, Wirman JA, McLaughlin C. Proliferative disorders of the breast as  
262 risk factors for breast cancer in a self-selected screened population: pathologic markers.  
263 *Radiology.* 1980;134(2):289-91.
- 264 43. Pettinato G, Panico L, de Rosa N, D'Antonio A, Bifano D, Avallone M. [Benign lesions of the  
265 breast]. *Ann Ital Chir.* 1997;68(2):151-66.
- 266 44. Myhre E. Is fibrocystic breast disease a pre-malignant state? *Acta Obstet Gynecol Scand*  
267 *Suppl.* 1984;123:189-91.
- 268 45. McFarlane ME. Benign breast diseases in an Afro-Caribbean population. *East Afr Med J.*  
269 2001;78(7):358-9.
- 270 46. Schnitt SJ. Benign breast disease and breast cancer risk: morphology and beyond. *Am J Surg*  
271 *Pathol.* 2003;27(6):836-41.
- 272 47. Rubin E, Visscher DW, Alexander RW, Urist MM, Maddox WA. Proliferative disease and  
273 atypia in biopsies performed for nonpalpable lesions detected mammographically. *Cancer.*  
274 1988;61(10):2077-82.
- 275 48. Salamat FM, Niakan BM, Keshtkar AP, Rafiei EM, Zendehtel MM. Subtypes of Benign Breast  
276 Disease as a Risk Factor of Breast Cancer: A Systematic Review and Meta Analyses. *Iran J*  
277 *Med Sci.* 2018;43(4):355-64.

278